CDBT logo

China Dasheng Biotechnology Company (CDBT)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

China Dasheng Biotechnology Company (CDBT) ist im Financial Services-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 38/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 16. März 2026
38/100 KI-Bewertung

China Dasheng Biotechnology Company (CDBT) Finanzdienstleistungsprofil

CEOGang Chen
Mitarbeiter689
HauptsitzLanzhou, CN
IPO-Jahr2008

China Dasheng Biotechnology Company, operating within the financial services sector as a shell company, focuses on the production and distribution of bacteria-based additives for livestock feed and crop cultivation in China. The company offers biological bacterium blends and preservatives, serving agricultural and livestock markets.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 16. März 2026

Investmentthese

China Dasheng Biotechnology Company's investment thesis hinges on its niche market in bacteria-based agricultural additives within China. With a negative P/E ratio of -7.14, the company's profitability is a concern. Key value drivers include expanding its product line and increasing market penetration in the agricultural sector. Growth catalysts involve leveraging its existing distribution network and capitalizing on the demand for sustainable agricultural practices. However, potential risks include the company's OTC listing, which implies lower liquidity and higher volatility, as reflected by its beta of 2.26. Further, the absence of dividends may deter income-seeking investors.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Operates in the financial services sector as a shell company.
  • Specializes in bacteria-based products for livestock feed and crop cultivation.
  • Based in Lanzhou, China, serving the People's Republic of China market.
  • P/E ratio of -7.14 indicates current lack of profitability.
  • Beta of 2.26 suggests high volatility compared to the market.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Specialized in bacteria-based agricultural additives.
  • Established presence in the Chinese market.
  • Offers a range of products for both crop and livestock applications.
  • Engages in real estate investment for diversification.

Schwaechen

  • Negative P/E ratio indicates lack of profitability.
  • OTC listing suggests higher risk and lower liquidity.
  • Limited geographic diversification outside of China.
  • Dependence on the agricultural sector, which can be cyclical.

Katalysatoren

  • Upcoming: Potential expansion into new geographic markets within China.
  • Upcoming: Development and launch of new bacteria-based product lines.
  • Ongoing: Increasing demand for sustainable agricultural practices.
  • Ongoing: Growing awareness of soil health and the benefits of biological additives.

Risiken

  • Potential: Limited financial disclosure due to OTC listing.
  • Potential: Lower liquidity and higher price volatility.
  • Ongoing: Competition from established agricultural companies.
  • Potential: Changes in agricultural regulations and policies.
  • Ongoing: Dependence on the agricultural sector, which can be cyclical.

Wachstumschancen

  • Expansion into organic farming markets: The growing demand for organic produce presents an opportunity for China Dasheng Biotechnology Company to tailor its products for organic farming practices. The global organic food market is projected to reach $323.1 billion by 2024, offering a substantial market for specialized bacteria-based additives. This expansion could involve developing certifications and formulations that meet organic standards, enhancing market access and brand reputation.
  • Development of specialized livestock feed additives: Focusing on developing specialized additives for specific livestock needs, such as poultry or swine, can create a competitive advantage. The global animal feed additives market is projected to reach $27.9 billion by 2027. Tailoring products to address specific nutritional deficiencies or health concerns in livestock can increase product value and customer loyalty.
  • Geographic expansion within China: Expanding distribution networks to reach underserved regions within China can significantly increase market penetration. China's agricultural sector is vast and diverse, with varying needs across different provinces. Establishing partnerships with local distributors and agricultural cooperatives can facilitate market entry and build brand awareness in new regions. This targeted approach can capitalize on regional agricultural strengths and address specific local needs.
  • Research and development of novel bacterial strains: Investing in research and development to discover and commercialize novel bacterial strains with enhanced efficacy can drive product innovation. The agricultural biotechnology sector is constantly evolving, with new discoveries leading to improved crop yields and disease resistance. Developing proprietary bacterial strains can create a competitive edge and protect market share through patents and intellectual property.
  • Strategic partnerships with agricultural technology companies: Collaborating with agricultural technology companies to integrate bacteria-based additives into broader agricultural solutions can enhance market reach and product value. This could involve partnerships with companies specializing in precision farming, data analytics, or irrigation systems. Integrating biological additives into these technologies can create synergistic benefits and provide comprehensive solutions for farmers.

Chancen

  • Expansion into organic farming markets.
  • Development of specialized livestock feed additives.
  • Geographic expansion within China.
  • Strategic partnerships with agricultural technology companies.

Risiken

  • Competition from established agricultural companies.
  • Changes in agricultural regulations and policies.
  • Economic downturns affecting the agricultural sector.
  • Potential for product liability claims.

Wettbewerbsvorteile

  • Proprietary bacteria strains and formulations.
  • Established distribution network within China.
  • Specialized knowledge in bacteria-based agricultural additives.
  • Brand recognition in the Chinese agricultural market.

Ueber CDBT

China Dasheng Biotechnology Company, formerly known as Max Nutrition, Inc., changed its name in March 2008 and is based in Lanzhou, China. The company, along with its subsidiaries, produces, markets, and distributes bacteria-based products used as additives for livestock feed and crop cultivation within the People's Republic of China. Their product line includes artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends, as well as biological preservatives. These products are designed to enhance soil quality, improve nutrient absorption, and reduce diseases in both crops and livestock. Specifically, the company provides AM/HM bacteria-based additives for crops, incorporating components like Bulgaria lactobacillus and beer microzyme. For livestock, the additives soften feed, restrain pathogenic bacteria, and supply beneficial nutrients. Additionally, China Dasheng Biotechnology Company offers FGW bacterial-based preservatives, used for preserving animal specimens and maintaining the freshness of agricultural produce. They also provide bacteria-based fertilizer for plants. The company also engages in residential and commercial real estate investment.

Was das Unternehmen tut

  • Produces bacteria-based additives for livestock feed.
  • Manufactures bacteria-based additives for crop cultivation.
  • Offers artificial microorganism (AM) based products.
  • Provides high-efficiency microorganism (HM) based products.
  • Distributes biological bacterium blends.
  • Supplies biological preservatives.
  • Engages in residential and commercial real estate investment.

Geschaeftsmodell

  • Sells bacteria-based additives directly to farmers and agricultural businesses.
  • Distributes products through a network of distributors and retailers.
  • Generates revenue from the sale of biological preservatives.
  • Derives income from real estate investments.

Branchenkontext

China Dasheng Biotechnology Company operates within the agricultural biotechnology sector, which is influenced by trends towards sustainable farming and increasing demand for higher crop yields. The competitive landscape includes companies offering similar biological additives and fertilizers. The market is driven by the need for environmentally friendly solutions and the growing awareness of soil health. China's agricultural sector is a significant market, but competition is intense with both domestic and international players vying for market share.

Wichtige Kunden

  • Farmers cultivating various crops.
  • Livestock producers raising animals for meat and dairy.
  • Agricultural businesses involved in crop and livestock production.
  • Scientific research institutions requiring animal specimen preservation.
  • Real estate tenants (residential and commercial).
KI-Zuversicht: 69% Aktualisiert: 16. März 2026

Finanzdaten

Chart & Info

China Dasheng Biotechnology Company (CDBT) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer CDBT verfuegbar.

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CDBT.

Kursziele

Wall-Street-Kurszielanalyse fuer CDBT.

MoonshotScore

38/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von CDBT auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Gang Chen

CEO

Gang Chen is the CEO of China Dasheng Biotechnology Company, leading a team of 689 employees. Information on his detailed career history, education, and previous roles is not available in the provided data. His leadership is pivotal in guiding the company's strategic direction and operational execution within the agricultural biotechnology sector.

Erfolgsbilanz: Due to limited information, specific achievements, strategic decisions, and company milestones under Gang Chen's leadership cannot be detailed. His role involves overseeing the production, marketing, and distribution of bacteria-based products for livestock feed and crop cultivation.

CDBT OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that China Dasheng Biotechnology Company may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and the trading of their securities can be highly speculative. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to increased risks for investors.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Given that China Dasheng Biotechnology Company trades on the OTC Other market, liquidity is likely to be limited. This typically translates to lower trading volumes and wider bid-ask spreads, making it potentially difficult for investors to buy or sell shares without significantly affecting the price. The limited liquidity can increase volatility and the risk of substantial price fluctuations.
OTC-Risikofaktoren:
  • Limited financial disclosure due to OTC Other listing.
  • Lower liquidity and wider bid-ask spreads.
  • Higher price volatility compared to exchange-listed stocks.
  • Potential for delisting or trading suspension due to non-compliance.
  • Increased risk of fraud or manipulation due to less regulatory oversight.
Sorgfaltspruefung-Checkliste:
  • Verify the company's financial statements and audit reports.
  • Assess the company's business operations and revenue streams.
  • Investigate the background and experience of the company's management team.
  • Review the company's legal and regulatory filings.
  • Evaluate the company's competitive position and market share.
  • Determine the level of trading volume and liquidity.
  • Consult with a financial advisor to assess the risks and potential rewards.
Legitimitaetssignale:
  • Operational business with products and services in the agricultural sector.
  • Presence in the Chinese market with a focus on bacteria-based additives.
  • Existence of a management team and employees.
  • Company history dating back to its initial incorporation as Max Nutrition, Inc.

China Dasheng Biotechnology Company Aktie: Wichtige Fragen beantwortet

What are the key factors to evaluate for CDBT?

China Dasheng Biotechnology Company (CDBT) currently holds an AI score of 38/100, indicating low score. Key strength: Specialized in bacteria-based agricultural additives.. Primary risk to monitor: Potential: Limited financial disclosure due to OTC listing.. This is not financial advice.

How frequently does CDBT data refresh on this page?

CDBT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven CDBT's recent stock price performance?

Recent price movement in China Dasheng Biotechnology Company (CDBT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized in bacteria-based agricultural additives.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider CDBT overvalued or undervalued right now?

Determining whether China Dasheng Biotechnology Company (CDBT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying CDBT?

Before investing in China Dasheng Biotechnology Company (CDBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding CDBT to a portfolio?

Potential reasons to consider China Dasheng Biotechnology Company (CDBT) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized in bacteria-based agricultural additives.. Additionally: Established presence in the Chinese market.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of CDBT?

Yes, most major brokerages offer fractional shares of China Dasheng Biotechnology Company (CDBT) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track CDBT's earnings and financial reports?

China Dasheng Biotechnology Company (CDBT) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CDBT earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Limited information available due to OTC listing and disclosure status.
  • AI analysis pending, which may provide further insights.
Datenquellen

Popular Stocks